Dow Jones
37.860,77 +125,66 (+0,33%) Nasdaq
15.885,75 +0,73 (+0,00%) Nikkei 225
38.471,20 -761,60 (-1,94%) EUR/USD
1,0624 -0,0002 (-0,02%) Bitcoin EUR
58.479,46 -1.939,89 (-3,21%) CMC Crypto 200
885,54 0,00 (0,00%)
Eloxx Pharmaceuticals, Inc. (ELOX)
| Chiusura precedente | 0,9801 |
| Aperto | 1,0000 |
| Denaro | 0,0000 x 800 |
| Lettera | 0,0000 x 800 |
| Min-Max giorno | 1,0000 - 1,0000 |
| Intervallo di 52 settimane | 0,4000 - 10,9000 |
| Volume | |
| Media Volume | 9.211 |
| Capitalizzazione | 3,144M |
| Beta (5 anni mensile) | 2,76 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -8,8800 |
| Prossima data utili | 16 apr 2024 - 21 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 30,00 |
GlobeNewswireEloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Podocyte Exact Morphology Procedure Results Podocyte Exact Morphology Procedure Results ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH Biopsy results support clinical benefit in all three patients as improvement of kidney morphology is consistent with reduction or stabilization of proteinuria during or up to 2 months post completion of dosing Renowned key opinion leaders recommend cont
GlobeNewswireEloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market
- GlobeNewswire
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement post-treatment in kidney biopsies demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport syndrome Eloxx intends to gain alignment with U.S. Food and Drug Adm
